Pronounced benefit of coronary Stenting and adjunctive Platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions

Previous trials testing stents compared with balloon angioplasty excluded patients with complex lesions and did not assess the effect of adjunctive platelet IIb/IIIa inhibition. This analysis sought to assess the effect of stenting and abciximab specifically for patients with complex lesions. Patien...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation (New York, N.Y.) N.Y.), 2000-07, Vol.102 (1), p.28-34
Hauptverfasser:	CURA, F. A, BHATT, D. L, TOPOL, E. J, LINCOFF, A. M, KAPADIA, S. R, LALLIER, P. L, ZIADA, K. M, WOLSKI, K. E, MOLITERNO, D. J, BRENER, S. J, ELLIS, S. G
Format:	Artikel
Sprache:	eng
Schlagworte:	Abciximab Aged Angioplasty, Balloon, Coronary Antibodies, Monoclonal - administration & dosage Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Combined Modality Therapy Coronary Artery Disease - mortality Coronary Artery Disease - therapy Female Humans Immunoglobulin Fab Fragments - administration & dosage Male Medical sciences Middle Aged Myocardial Ischemia - mortality Myocardial Ischemia - therapy Pharmacology. Drug treatments Platelet Aggregation Inhibitors - administration & dosage Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors Stents Survival Analysis Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Previous trials testing stents compared with balloon angioplasty excluded patients with complex lesions and did not assess the effect of adjunctive platelet IIb/IIIa inhibition. This analysis sought to assess the effect of stenting and abciximab specifically for patients with complex lesions. Patients with complex lesions (long, tandem, severely calcified, restenotic, thrombotic, or ostial; total occlusions; bifurcations; saphenous vein grafts; and multivessel interventions) from the Evaluation of PTCA to Improve Long-Term Outcome by c7E3 GP IIb/IIIa Receptor Blockade (EPILOG) and the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) trials were included in the analysis. The 1-year combined death or myocardial infarction rates in the 4 treatment groups were as follows: balloon angioplasty/placebo, 14.2%; stent/placebo, 15.8%; balloon angioplasty/abciximab, 7.6%; and stent/abciximab, 8.0% (P
ISSN:	0009-7322 1524-4539
DOI:	10.1161/01.CIR.102.1.28